ArticleAtherosclerosis plus2024

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins.

Chaoxuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.